Literature DB >> 21779474

Functional analysis and molecular targeting of aurora kinases a and B in advanced melanoma.

Xiaolei Wang1, Stergios J Moschos, Dorothea Becker.   

Abstract

Over the past few years, high-throughput analyses have provided important novel insights into molecular pathways that play a crucial role in the progression from early to advanced melanoma, and at the same time, they have led to the identification of genes that as part of melanoma progression are upregulated in advanced melanoma. In the present study, we provide evidence that Aurora kinases A and B, 2 key regulators of M phase progression, are upregulated to high levels with progression from melanoma in situ to primary and metastatic melanoma and that inhibiting the expression of these 2 genes by RNA interference or blocking their function with an Aurora kinase-specific small-molecule inhibitor severely impairs melanoma cell proliferation and cell cycle progression and induces melanoma cell apoptosis. In addition, we present the results of systemic treatment of human melanoma xenografts with an Aurora kinase small-molecule inhibitor as well as Aurora kinase targeting vectors.

Entities:  

Keywords:  Aurora kinases; melanoma; molecular targeting; xenograft studies

Year:  2010        PMID: 21779474      PMCID: PMC3092253          DOI: 10.1177/1947601910388936

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  24 in total

1.  A small C-terminal sequence of Aurora B is responsible for localization and function.

Authors:  Laetitia Scrittori; Dimitrios A Skoufias; Fabienne Hans; Véronique Gerson; Paolo Sassone-Corsi; Stefan Dimitrov; Robert L Margolis
Journal:  Mol Biol Cell       Date:  2004-10-27       Impact factor: 4.138

2.  The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.

Authors:  Stuart Emanuel; Catherine A Rugg; Robert H Gruninger; Ronghui Lin; Angel Fuentes-Pesquera; Peter J Connolly; Steven K Wetter; Beth Hollister; Walter W Kruger; Cheryl Napier; Linda Jolliffe; Steven A Middleton
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.

Authors:  Amanda Pfaff Smith; Keith Hoek; Dorothea Becker
Journal:  Cancer Biol Ther       Date:  2005-09-09       Impact factor: 4.742

4.  The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion.

Authors:  Kelly Watson-Hurst; Dorothea Becker
Journal:  Cancer Biol Ther       Date:  2006-10-26       Impact factor: 4.742

5.  Osteopontin expression correlates with melanoma invasion.

Authors:  Youwen Zhou; Derek L Dai; Magdalena Martinka; Mingwan Su; Yi Zhang; Eric I Campos; Irene Dorocicz; Liren Tang; David Huntsman; Colleen Nelson; Vincent Ho; Gang Li
Journal:  J Invest Dermatol       Date:  2005-05       Impact factor: 8.551

6.  SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas.

Authors:  S J Moschos; A P Smith; M Mandic; C Athanassiou; K Watson-Hurst; D M Jukic; H D Edington; J M Kirkwood; D Becker
Journal:  Oncogene       Date:  2007-02-12       Impact factor: 9.867

7.  Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.

Authors:  Jochen Jaeger; Dirk Koczan; Hans-Juergen Thiesen; Saleh M Ibrahim; Gerd Gross; Rainer Spang; Manfred Kunz
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

8.  Osteopontin as a molecular prognostic marker for melanoma.

Authors:  Javier Rangel; Mehdi Nosrati; Sima Torabian; Ladan Shaikh; Stanley P L Leong; Chris Haqq; James R Miller; Richard W Sagebiel; Mohammed Kashani-Sabet
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

9.  Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation.

Authors:  D Becker; P L Lee; U Rodeck; M Herlyn
Journal:  Oncogene       Date:  1992-11       Impact factor: 9.867

Review 10.  Chromosomal passengers: conducting cell division.

Authors:  Sandrine Ruchaud; Mar Carmena; William C Earnshaw
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

View more
  10 in total

1.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

2.  Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Authors:  Arati Sharma; SubbaRao V Madhunapantula; Raghavendra Gowda; Arthur Berg; Rogerio I Neves; Gavin P Robertson
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

3.  Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.

Authors:  Caroline Bonet; Sandy Giuliano; Mickaël Ohanna; Karine Bille; Maryline Allegra; Jean-Philippe Lacour; Philippe Bahadoran; Stéphane Rocchi; Robert Ballotti; Corine Bertolotto
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

4.  The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines.

Authors:  Lifang Xie; Frank L Meyskens
Journal:  Melanoma Res       Date:  2013-04       Impact factor: 3.599

5.  Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.

Authors:  Letizia Porcelli; Gabriella Guida; Anna E Quatrale; Tiziana Cocco; Letizia Sidella; Immacolata Maida; Rosa M Iacobazzi; Anna Ferretta; Diana A Stolfa; Sabino Strippoli; Stefania Guida; Stefania Tommasi; Michele Guida; Amalia Azzariti
Journal:  J Transl Med       Date:  2015-01-27       Impact factor: 5.531

6.  Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor.

Authors:  Lili Han; Peiling Wang; Yang Sun; Sijing Liu; Jun Dai
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

7.  Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation.

Authors:  Luca Quattrini; Vito Coviello; Stefania Sartini; Teresa Di Desidero; Paola Orlandi; Yi-Yu Ke; Kai-Lun Liu; Hsing-Pang Hsieh; Guido Bocci; Concettina La Motta
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

8.  Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.

Authors:  Yan Liu; Oriana E Hawkins; Yingjun Su; Anna E Vilgelm; Tammy Sobolik; Yee-Mon Thu; Sara Kantrow; Ryan C Splittgerber; Sarah Short; Katayoun I Amiri; Jeffery A Ecsedy; Jeffery A Sosman; Mark C Kelley; Ann Richmond
Journal:  EMBO Mol Med       Date:  2012-11-25       Impact factor: 12.137

9.  AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

Authors:  Emilia Caputo; Roberta Miceli; Maria Letizia Motti; Rosarita Taté; Federica Fratangelo; Gerardo Botti; Nicola Mozzillo; Maria Vincenza Carriero; Ernesta Cavalcanti; Giuseppe Palmieri; Gennaro Ciliberto; Giuseppe Pirozzi; Paolo Antonio Ascierto
Journal:  J Transl Med       Date:  2014-07-31       Impact factor: 5.531

10.  Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening.

Authors:  Katya Nardou; Michael Nicolas; Fabien Kuttler; Katarina Cisarova; Elifnaz Celik; Mathieu Quinodoz; Nicolo Riggi; Olivier Michielin; Carlo Rivolta; Gerardo Turcatti; Alexandre Pierre Moulin
Journal:  Cancers (Basel)       Date:  2022-03-19       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.